Indivior PLC (LON:INDV - Get Free Report)'s stock price traded down 17% during trading on Thursday . The stock traded as low as GBX 548.71 ($6.93) and last traded at GBX 720.60 ($9.10). 2,904,792 shares traded hands during trading, an increase of 294% from the average session volume of 737,710 shares. The stock had previously closed at GBX 868 ($10.97).
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group reiterated a "buy" rating and issued a GBX 1,800 ($22.74) target price on shares of Indivior in a research note on Tuesday, December 17th.
View Our Latest Analysis on Indivior
Indivior Stock Performance
The firm has a market capitalization of £1.08 billion, a PE ratio of -570.87, a PEG ratio of -5.57 and a beta of 0.19. The company has a quick ratio of 1.52, a current ratio of 0.83 and a debt-to-equity ratio of -170.06. The company has a 50-day moving average of GBX 920.11 and a 200 day moving average of GBX 850.81.
About Indivior
(
Get Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Read More
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
